New cell therapy YTB323 tested in progressive MS patients
NCT ID NCT06675864
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This early-phase trial tests a new treatment called YTB323 in 28 adults with non-active progressive multiple sclerosis (MS). The goal is to check if the therapy is safe and to see how it affects disability and disease progression. Participants receive a single dose, and researchers will monitor side effects and changes in their condition over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
-
Novartis Investigative Site
RECRUITINGBron, 69677, France
-
Novartis Investigative Site
RECRUITINGMontpellier, 34090, France
-
Novartis Investigative Site
RECRUITINGNancy, 54035, France
-
Novartis Investigative Site
RECRUITINGRennes, 35033, France
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16132, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20132, Italy
-
Novartis Investigative Site
RECRUITINGBarcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMajadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
RECRUITINGMálaga, 29010, Spain
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGLausanne, 1011, Switzerland
-
Novartis Investigative Site
RECRUITINGZurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.